HARMONY BIOSC.HLD.-,00001 Logo
US4131971040
A2QBSF
HRMY

HARMONY BIOSC.HLD.-,00001

Previsión

El precio objetivo medio de los analistas es de 45,17 € (+50,02 %). La mediana es de 44,65 € (+48,29 %).

Comprar
  8
Mantener
  3
Vender
  2

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Harmony Biosciences outlines second growth chapter with BP-205 and acquisition plans

    Harmony is building on revenue driver WAKIX (on track for over $1 billion) and a broader pipeline approach. The company has about $963 million in cash, positions BP-205 as a leading orexin‑2 agonist and plans two to three business-development transactions expected to generate revenue in 2028–2032. In parallel, Harmony is defending WAKIX’s patent portfolio against generics and anticipates loss of exclusivity in March 2030. Several clinical milestones for BP-205 are targeted for late 2024 to mid-2026. » Más en de.investing.com


  • Harmony Biosciences reaches 52-week high after strong Wakix numbers

    Harmony Biosciences shares rose to a new 52-week high of $42.70 and have a market capitalization of about $2.49 billion. In the second quarter, adjusted earnings per share of $1.28 beat expectations, and Wakix revenue hit a record $261.3 million, confirming the full-year guidance of $1.00–1.04 billion. Analysts remain positive (including outperform ratings with price targets of $60–70), despite ongoing IP disputes and competition from orexin agonists. InvestingPro sees the stock at a fair value of $59.06 and rates the financial condition as "EXCELLENT". » Más en de.investing.com


  • Harmony Biosciences presents strategy following WAKIX and expands CNS pipeline

    Harmony outlines three strategic pillars: expanding the pitolisant franchise with Pitolisant GR (PDUFA April 27) and Pitolisant HD; advancing BP-205 as a potential best-in-class orexin-2 agonist; and developing EPX-100 for rare epilepsies. WAKIX delivered record quarterly sales and funds the pipeline growth, while key milestones are mostly expected in 2027/2028. BP-205 showed strong efficacy, rapid absorption and no relevant safety signals in early studies; EPX-100 demonstrated substantial seizure reductions in Dravet syndrome. The stock closed at $38.50 (-3.19%). » Más en de.investing.com


  • Harmony Biosciences posts strong Q1 results, keeps full-year revenue guidance above $1 billion

    Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% year-over-year increase driven by continued adoption of WAKIX (pitolisant). Management reaffirmed full-year 2026 net revenue guidance of over $1 billion and highlighted strong operating leverage and cash generation funding its late-stage pipeline. The company is pursuing pediatric narcolepsy approval and exploring indications including idiopathic hypersomnia and Prader-Willi syndrome, supporting investor optimism about lifecycle and pipeline growth. » Más en finance.yahoo.com


  • Harmony Biosciences: WAKIX grows, heavy investments weigh on quarterly profit

    Harmony reported Q1 2026 results: WAKIX revenue rose 17% to $215.4 million but missed consensus, and diluted earnings per share fell to $0.55, well below expectations. Management reaffirmed the full-year revenue guidance of $1.0–1.04 billion, attributing the earnings miss to high strategic investments, license costs and increased R&D spending. The company holds about $870.5 million in cash and highlights growth drivers such as enteric-coated and high‑dose pitolisant programs, a broad pipeline and legal actions to defend patents. Despite near-term profitability pressure, Harmony sees a clear path for WAKIX to reach the billion-dollar mark and plans to step up business development transactions. » Más en de.investing.com

Datos financieros

En el último trimestre, HARMONY BIOSC.HLD.-,00001 tuvo unos ingresos de 237,41 M € y un beneficio neto de 42,55 M €

(EUR) septiembre de 2026
YoY
Ingresos 237,41 M 16,35 %
Beneficio bruto 166,18 M 8,46 %
Beneficio neto 42,55 M 1,83 %
EBITDA 60,28 M 3,70 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
1771,9 M €
Número de acciones
58,72 M
Máximo/mínimo de 52 semanas
39,63 € - 23,60 €
Dividendos No
Beta
0,98
Ratio P/E
10,75
Ratio PEG
-2,18
Ratio P/B
1,80
Ratio P/S
1,97

Perfil de la empresa

Harmony Biosciences Holdings, Inc., una empresa farmacéutica en fase comercial, desarrolla y comercializa terapias para pacientes con trastornos neurológicos raros en Estados Unidos. Su producto, WAKIX, es un medicamento para el tratamiento de la somnolencia diurna excesiva en pacientes adultos con narcolepsia. La empresa era conocida anteriormente como Harmony Biosciences II, Inc. y cambió su nombre a Harmony Biosciences Holdings, Inc. en febrero de 2020. Harmony Biosciences Holdings, Inc. se constituyó en 2017 y tiene su sede en Plymouth Meeting, Pensilvania.

Nombre
HARMONY BIOSC.HLD.-,00001
CEO
Jeffrey Dayno
Sede Plymouth Meeting, pa
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
19/08/2020
Empleados 293

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
HRMY
🍪

Parqet  usa cookies. Más información